RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus-Based therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…
Matched conditions: RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for hard-to-treat t-cell lymphoma: drug combo plus radiation before transplant
Disease control Recruiting nowThis study tests a new mix of two chemotherapy drugs (pralatrexate and bendamustine) plus low-dose total-body radiation given before a donor stem cell transplant. It is for people with T-cell lymphoma that has come back or not responded to prior treatments. The goal is to see if …
Matched conditions: RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC